PAQ Therapeutics scores $30M to unleash “Pac-Man” drugs on neuro disease
Startup PAQ Therapeutics is developing drugs that work like Pac-Man, gobbling up components of a cell associated with disease. The biotech has closed $30 million in financing to continue its research, with a neurodegenerative disorder as its lead disease target.